The predominant expression of p110δ in white blood cells50,51 has shifted the interest in the biology of the PI3K p110δ pathway toward immune disorders and haematologic cancers52; p110δ-selective inhibitors have been studied in multiple haematologic malignancies25,26. The gene discussed is PIK3CA; the disease is immune system disorder.